EUVIMEDEUVIMED entdecken
VergleichsstudieMetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis

Ali Mushtaq, Eman Nayaz Ahmed iD, Roaa Aljumaa, Abdel Rahman E'mar, Osamah Badwan, Omer Ashruf, Ahmad Elshaer, Abdullah Shaik, Mohanad Baroudi, Rohit Moudgil iD, Moaath K Mustafa Ali iD

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag102 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Oncologist, online erschienen am 23.03.2026. Verfasst von Ali Mushtaq und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, United States. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Atrial Fibrillation, Cardiotoxicity, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The first-generation Bruton’s tyrosine kinase inhibitor (BTKi), ibrutinib, is associated with significant cardiotoxicity. Second-generation agents were developed to mitigate this risk and offer an improved safety profile. This systematic review and meta-analysis of six direct comparator studies compares the cardiac safety profiles of first- and second-generation BTKi.

Methods

We systematically searched Medline, Embase, and Cochrane for studies directly comparing first- and second-generation BTKi. Data from 6 studies, encompassing 14 455 patients (12 816 in the first-generation arm and 1639 in the second-generation arm), were included. The primary outcomes were the incidence of atrial fibrillation (AF) and cardiac events, defined by the Medical Dictionary for Regulatory Activities system organ class. All pooled analyses were conducted using a random-effects model. Publication bias was evaluated visually using a funnel plot, quantitatively with Egger’s regression test, and corrected using the Duval and Tweedie trim-and-fill method.

Results

Compared to second-generation agents, ibrutinib was associated with a significantly higher risk of AF (OR 2.50, 95% CI, 1.97-3.17), total cardiac events (OR 1.53, 95% CI, 1.18-1.99), and heart failure (OR 2.08, 95% CI, 1.13-3.83). This translated to a 3-fold higher rate of treatment discontinuation for a cardiac cause (OR 3.32, 95% CI, 1.46-7.55). No significant difference in all-cause mortality was found.

Conclusion

Second-generation BTKi may provide a more favorable cardiovascular safety profile than ibrutinib, resulting in fewer key cardiac events and less treatment-limiting toxicity. These findings should inform clinical decision-making, especially for patients with increased risk for cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Agammaglobulinaemia Tyrosine KinaseAtrial FibrillationCardiotoxicityProtein Kinase InhibitorsPyrimidinesHumansAdeninePiperidinesPyrazoles

Stichwörter der Autor:innen

B-cell malignancyBruton’s tyrosine kinase inhibitorsacalabrutinibatrial fibrillationcardiac safety profilecardiotoxicitycardiovascular outcomesibrutinibmeta-analysiszanubrutinib

Substanzen

AdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidines

Autor:innen und Institutionen

  • Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, 44195, United States.
  • College of Medicine, Alfaisal University, Riyadh, 11533, Saudi Arabia.
  • Department of Cardiology, Cleveland Clinic, Cleveland, OH, 44195, United States.
  • Indiana University School of Medicine Department of Internal Medicine, Indianapolis, IN, 46202, United States.
  • Department of Medicine, Creighton University School of Medicine, Omaha, NE, 68178, United States.
  • Department of Internal Medicine Henry Ford St. John Hospital, Detroit, MI, 48236, United States.

ORCID-Profile: Eman Nayaz Ahmed, Rohit Moudgil, Moaath K Mustafa Ali

Zitieren

APA

Mushtaq, A., Ahmed, E. N., Aljumaa, R., E'mar, A. R., Badwan, O., Ashruf, O., Elshaer, A., Shaik, A., Baroudi, M., Moudgil, R., & Mustafa Ali, M. K. (2026). Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag102

Vancouver

Mushtaq A, Ahmed EN, Aljumaa R, E'mar AR, Badwan O, Ashruf O, et al. Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag102

BibTeX
@article{Mushtaq2026,
  author = {Mushtaq, Ali and Ahmed, Eman Nayaz and Aljumaa, Roaa and E'mar, Abdel Rahman and Badwan, Osamah and Ashruf, Omer and Elshaer, Ahmad and Shaik, Abdullah and Baroudi, Mohanad and Moudgil, Rohit and Mustafa Ali, Moaath K},
  title = {Cardiac safety profiles of first-generation vs second-generation BTK inhibitors: a meta-analysis},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag102}
}
Kostenlos starten →